Review
Geriatrics & Gerontology
Eleni Karantali, Dimitrios Kazis, Symela Chatzikonstantinou, Fivos Petridis, Ioannis Mavroudis
Summary: Neurofilament light chain (NfL) may play a role in differentiating patients with frontotemporal dementia from healthy controls, patients with Alzheimer's dementia, and psychiatric disorders. Additionally, higher levels of NfL were observed in patients with semantic primary progressive aphasia (PPA) compared to behavioral FTD and non-fluent PPA patients, suggesting the utility of NfL in distinguishing specific FTD subgroups. Further research exploring the use of NfL in frontotemporal dementia is warranted.
AGING CLINICAL AND EXPERIMENTAL RESEARCH
(2021)
Article
Clinical Neurology
Anuschka Silva-Spinola, Marisa Lima, Maria Joao Leitao, Joao Duraes, Miguel Tabuas-Pereira, Maria Rosario Almeida, Isabel Santana, Ines Baldeiras
Summary: The study on FTD and its subtypes found that levels of NfL in CSF and serum can serve as biomarkers for the disease and are associated with cognitive decline. Genetic cases, especially FTD-GRN, have higher NfL levels. These findings suggest that NfL may have potential value in evaluating disease severity and developing therapies for FTD.
EUROPEAN JOURNAL OF NEUROLOGY
(2022)
Article
Neurosciences
Suyi Ooi, Sheila K. Patel, Dhamidhu Eratne, Christopher Kyndt, Natalie Reidy, Courtney Lewis, Sarah C. M. Lee, David Darby, Amy Brodtmann
Summary: The study found that plasma neurofilament light chain (NfL) levels can help distinguish between frontotemporal dementia (FTD) syndromes and mimics, but may not fully differentiate slow progressors; NfL levels are higher in FTD patients. More patient data is needed to strengthen diagnostic utility.
JOURNAL OF ALZHEIMERS DISEASE
(2022)
Article
Cell Biology
Tania F. Gendron, Michael G. Heckman, Launia J. White, Austin M. Veire, Otto Pedraza, Alexander R. Burch, Andrea C. Bozoki, Bradford C. Dickerson, Kimiko Domoto-Reilly, Tatiana Foroud, Leah K. Forsberg, Douglas R. Galasko, Nupur Ghoshal, Neill R. Graff-Radford, Murray Grossman, Hilary W. Heuer, Edward D. Huey, Ging-Yuek R. Hsiung, David J. Irwin, Daniel Kaufer, Gabriel C. Leger, Irene Litvan, Joseph C. Masdeu, Mario F. Mendez, Chiadi U. Onyike, Belen Pascual, Aaron Ritter, Erik D. Roberson, Julio C. Rojas, Maria Carmela Tartaglia, Zbigniew K. Wszolek, Howard Rosen, Bradley F. Boeve, Adam L. Boxer, Leonard Petrucelli
Summary: Blood neurofilament light (NfL) shows promise as a biomarker for frontotemporal dementia (FTD), aiding in early diagnosis, participant selection for prevention or early treatment trials, and improving patient care and treatment outcome estimations.
CELL REPORTS MEDICINE
(2022)
Article
Geriatrics & Gerontology
Helena Sophia Gleerup, Federica Sanna, Peter Hogh, Joel Simren, Kaj Blennow, Henrik Zetterberg, Steen Gregers Hasselbalch, Nicholas J. Ashton, Anja Hviid Simonsen
Summary: The study found that while NfL can be detected in saliva, it is not reflective of neurodegeneration in the brain and does not correlate with levels of AD biomarkers in CSF.
FRONTIERS IN AGING NEUROSCIENCE
(2021)
Article
Neurosciences
Pedro Lopes das Nevesa, Joao Duraes, Anuschka Silva-Spinola, Marisa Lima, Maria Joao Leitao, Miguel Tabuas-Pereira, Isabel Santana, Ines Baldeiras
Summary: Serum light-chain neurofilaments (sNfL) could serve as a potential minimally invasive biomarker for the diagnosis of patients with cognitive symptoms, showing a strong correlation with cerebrospinal fluid (CSF) biomarkers.
JOURNAL OF ALZHEIMERS DISEASE
(2023)
Article
Neurosciences
Giulia Coarelli, Frederic Darios, Emilien Petit, Karim Dorgham, Isaac Adanyeguh, Elodie Petit, Alexis Brice, Fanny Mochel, Alexandra Durr
Summary: This study found that in autosomal dominant spinocerebellar ataxias (SCAs), NfL levels can better predict clinical manifestations and brain changes. Additionally, NfL levels may help refine inclusion criteria for carriers in clinical trials.
NEUROBIOLOGY OF DISEASE
(2021)
Article
Medicine, General & Internal
Jia-Hung Chen, Lung Chan, Chen-Chih Chung, Oluwaseun Adebayo Bamodu, Chien-Tai Hong
Summary: Elevated blood neurofilament light chain is being increasingly recognized as a diagnostic and outcome-predicting biomarker for neurological diseases, but its implications in Parkinson's disease remain unclear. Studies have shown conflicting data on blood NfL levels in PD cohorts, possibly due to demographic heterogeneity. By adjusting for age and gender, the comparability of NfL levels between different PD studies can be enhanced, helping to eliminate conflicting factors and enhance the understanding of this biomarker's significance.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Neurosciences
Federico Verde, Markus Otto, Vincenzo Silani
Summary: ALS and FTD are currently incurable neurodegenerative diseases lacking specific neurochemical biomarkers, but NFL has shown considerable progress as a biomarker in both diseases, distinguishing them from mimic conditions and providing prognostic information.
FRONTIERS IN NEUROSCIENCE
(2021)
Article
Clinical Neurology
Julio C. Rojas, Ping Wang, Adam M. Staffaroni, Carolin Heller, Yann Cobigo, Amy Wolf, Sheng-Yang M. Goh, Peter A. Ljubenkov, Hilary W. Heuer, Jamie C. Fong, Joanne B. Taylor, Eliseo Veras, Linan Song, Andreas Jeromin, David Hanlon, Lili Yu, Arvind Khinikar, Rajeev Sivasankaran, Agnieszka Kieloch, Marie-Anne Valentin, Anna M. Karydas, Laura L. Mitic, Rodney Pearlman, John Kornak, Joel H. Kramer, Bruce L. Miller, Kejal Kantarci, David S. Knopman, Neill Graff-Radford, Leonard Petrucelli, Rosa Rademakers, David J. Irwin, Murray Grossman, Eliana Marisa Ramos, Giovanni Coppola, Mario F. Mendez, Yvette Bordelon, Bradford C. Dickerson, Nupur Ghoshal, Edward D. Huey, Ian R. Mackenzie, Brian S. Appleby, Kimiko Domoto-Reilly, Ging-Yuek R. Hsiung, Arthur W. Toga, Sandra Weintraub, Daniel I. Kaufer, Diana Kerwin, Irene Litvan, Chiadikaobi U. Onyike, Alexander Pantelyat, Erik D. Roberson, Maria C. Tartaglia, Tatiana Foroud, Weiping Chen, Julie Czerkowicz, Danielle L. Graham, John C. van Swieten, Barbara Borroni, Raquel Sanchez-Valle, Fermin Moreno, Robert Laforce, Caroline Graff, Matthis Synofzik, Daniela Galimberti, James B. Rowe, Mario Masellis, Elizabeth Finger, Rik Vandenberghe, Alexandre de Mendonca, Fabrizio Tagliavini, Isabel Santana, Simon Ducharme, Chris R. Butler, Alexander Gerhard, Johannes Levin, Adrian Danek, Markus Otto, Sandro Sorbi, David M. Cash, Rhian S. Convery, Martina Bocchetta, Martha Foiani, Caroline V. Greaves, Georgia Peakman, Lucy Russell, Imogen Swift, Emily Todd, Jonathan D. Rohrer, Bradley F. Boeve, Howard J. Rosen, Adam L. Boxer, ALLFTD Consortium, GENFI Consortium
Summary: Plasma neurofilament light chain (NfL) can identify asymptomatic carriers of FTLD-causing mutations at risk of disease progression, providing potential for selecting participants in prevention clinical trials.
Article
Clinical Neurology
Julio C. Rojas, Ping Wang, Adam M. Staffaroni, Carolin Heller, Yann Cobigo, Amy Wolf, Sheng-Yang M. Goh, Peter A. Ljubenkov, Hilary W. Heuer, Jamie C. Fong, Joanne B. Taylor, Eliseo Veras, Linan Song, Andreas Jeromin, David Hanlon, Lili Yu, Arvind Khinikar, Rajeev Sivasankaran, Agnieszka Kieloch, Marie-Anne Valentin, Anna M. Karydas, Laura L. Mitic, Rodney Pearlman, John Kornak, Joel H. Kramer, Bruce L. Miller, Kejal Kantarci, David S. Knopman, Neill Graff-Radford, Leonard Petrucelli, Rosa Rademakers, David J. Irwin, Murray Grossman, Eliana Marisa Ramos, Giovanni Coppola, Mario F. Mendez, Yvette Bordelon, Bradford C. Dickerson, Nupur Ghoshal, Edward D. Huey, Ian R. Mackenzie, Brian S. Appleby, Kimiko Domoto-Reilly, Ging-Yuek R. Hsiung, Arthur W. Toga, Sandra Weintraub, Daniel I. Kaufer, Diana Kerwin, Irene Litvan, Chiadikaobi U. Onyike, Alexander Pantelyat, Erik D. Roberson, Maria C. Tartaglia, Tatiana Foroud, Weiping Chen, Julie Czerkowicz, Danielle L. Graham, John C. van Swieten, Barbara Borroni, Raquel Sanchez-Valle, Fermin Moreno, Robert Laforce, Caroline Graff, Matthis Synofzik, Daniela Galimberti, James B. Rowe, Mario Masellis, Elizabeth Finger, Rik Vandenberghe, Alexandre de Mendonca, Fabrizio Tagliavini, Isabel Santana, Simon Ducharme, Chris R. Butler, Alexander Gerhard, Johannes Levin, Adrian Danek, Markus Otto, Sandro Sorbi, David M. Cash, Rhian S. Convery, Martina Bocchetta, Martha Foiani, Caroline V. Greaves, Georgia Peakman, Lucy Russell, Imogen Swift, Emily Todd, Jonathan D. Rohrer, Bradley F. Boeve, Howard J. Rosen, Adam L. Boxer
Summary: Plasma neurofilament light chain (NfL) can identify asymptomatic carriers of FTLD-causing mutations at risk of disease progression. Higher baseline NfL levels are associated with worse clinical progression, neuropsychological function, and brain atrophy.
Review
Neurosciences
Samir Abu-Rumeileh, Piero Parchi
Summary: Rapidly progressive dementia refers to conditions causing rapid neurological deterioration associated with cognitive decline, such as Creutzfeldt-Jakob disease. The neurofilament light chain protein could serve as a biofluid marker in differential diagnosis and prognostic assessment in RPDs.
FRONTIERS IN NEUROSCIENCE
(2021)
Article
Clinical Neurology
Salvatore Mazzeo, Assunta Ingannato, Giulia Giacomucci, Alberto Manganelli, Valentina Moschini, Juri Balestrini, Arianna Cavaliere, Carmen Morinelli, Giulia Galdo, Filippo Emiliani, Diletta Piazzesi, Chiara Crucitti, Daniele Frigerio, Cristina Polito, Valentina Berti, Silvia Bagnoli, Sonia Padiglioni, Sandro Sorbi, Benedetta Nacmias, Valentina Bessi
Summary: Plasma neurofilament light chain (NfL) can accurately predict Alzheimer's disease and the progression of cognitive decline, serving as an important non-invasive tool for early diagnosis.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Medicine, General & Internal
Andrew D. Nguyen, Theodore K. Malmstrom, Geetika Aggarwal, Douglas K. Miller, Bruno Vellas, John E. Morley
Summary: This study found a positive association between serum NfL levels and mortality in late middle-aged and older individuals, with higher serum NfL levels associated with reduced survival. The results suggest that serum NfL levels may be a useful biomarker for all-cause mortality, but further studies are needed to understand the biological mechanisms underlying this association.
Article
Clinical Neurology
Alberto Benussi, Nicholas J. Ashton, Thomas K. Karikari, Antonella Alberici, Claudia Saraceno, Roberta Ghidoni, Luisa Benussi, Henrik Zetterberg, Kaj Blennow, Barbara Borroni
Summary: The prodromal phase of frontotemporal dementia has a high rate of progression to fully symptomatic disease at 1-year follow-up, with high serum NfL levels serving as a strong predictor of disease progression.
ALZHEIMERS RESEARCH & THERAPY
(2021)
Article
Psychiatry
Daniel Kapustin, Shadi Zarei, Wei Wang, Malcolm A. Binns, Paula M. McLaughlin, Agessandro Abrahao, Sandra E. Black, Michael Borrie, David Breen, Leanna Casaubon, Dar Dowlatshahi, Elizabeth Finger, Corinne E. Fischer, Andrew Frank, Morris Freedman, David Grimes, Ayman Hassan, Mandar Jog, Donna Kwan, Anthony Lang, Brian Levine, Jennifer Mandzia, Connie Marras, Mario Masellis, Joseph B. Orange, Stephen Pasternak, Alicia Peltsch, Bruce G. Pollock, Tarek K. Rajji, Angela Roberts, Demetrios Sahlas, Gustavo Saposnik, Dallas Seitz, Christen Shoesmith, Alisia Southwell, Thomas D. L. Steeves, Kelly Sunderland, Richard H. Swartz, Brian Tan, David F. Tang-Wai, Maria Carmela Tartaglia, Angela Troyer, John Turnbull, Lorne Zinman, Sanjeev Kumar
Summary: Neuropsychiatric symptoms (NPS) vary in frequency and severity across different neurodegenerative disorders, with frontotemporal dementia (FTD) having the highest occurrence. The association between NPS burden and function differs among disorders, highlighting the need for individualized clinical interventions.
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE
(2023)
Article
Clinical Neurology
Marco Bolchini, Francesca Schiano di Cola, Giulia Ceccardi, Salvatore Caratozzolo, Paolo Liberini, Renata Rao, Alessandro Padovani
Summary: The aim of this study was to evaluate the efficacy of erenumab 140 mg in the treatment of migraine disability and intensity in patients with high-frequency episodic migraine. The results showed a significant and progressive improvement in migraine pain intensity and disability during re-treatment.
EUROPEAN NEUROLOGY
(2023)
Article
Computer Science, Interdisciplinary Applications
Jieqing Jiao, Fiona Heeman, Rachael Dixon, Catriona Wimberley, Isadora Lopes Alves, Juan Domingo Gispert, Adriaan A. Lammertsma, Bart N. M. van Berckel, Casper da Costa-Luis, Pawel Markiewicz, David M. Cash, M. Jorge Cardoso, Sebastien Ourselin, Maqsood Yaqub, Frederik Barkhof
Summary: This paper introduces a Python-based software package called NiftyPAD for versatile analyses of dynamic PET data. NiftyPAD can handle dual-time window scans, pharmacokinetic modelling, and PET data-based motion correction. It produces comparable results with established software packages and has the advantages of multi-platform usage, modular setup, and lightweight.
Editorial Material
Clinical Neurology
Christopher R. S. Belder, Anthipa Chokesuwattanaskul, Charles R. Marshall, Chris J. D. Hardy, Jonathan D. Rohrer, Jason D. Warren
FRONTIERS IN NEUROLOGY
(2023)
Article
Clinical Neurology
Lize C. Jiskoot, Lucy L. Russell, Georgia Peakman, Rhian S. Convery, Caroline V. Greaves, Martina Bocchetta, Jackie M. Poos, Harro Seelaar, Lucia A. A. Giannini, John C. van Swieten, Rick van Minkelen, Yolande A. L. Pijnenburg, James B. Rowe, Barbara Borroni, Daniela Galimberti, Mario Masellis, Carmela Tartaglia, Elizabeth Finger, Chris R. Butler, Caroline Graff, Robert Laforce Jr, Raquel Sanchez-Valle, Alexandre de Mendonca, Fermin Moreno, Matthis Synofzik, Rik Vandenberghe, Simon Ducharme, Isabelle le Ber, Johannes Levin, Markus Otto, Florence Pasquier, Isabel Santana, David M. Cash, David Thomas, Jonathan D. Rohrer
Summary: The Benson Complex Figure Test (BCFT) shows potential as a sensitive cognitive marker for frontotemporal dementia (FTD). Differences were found in BCFT Copy, Recall, and Recognition scores between presymptomatic and symptomatic FTD mutation carriers, with correlations to cognitive function and neuroimaging results. These findings suggest limited potential of BCFT as a cognitive biomarker for upcoming clinical trials in presymptomatic to early-stage FTD.
JOURNAL OF THE NEUROLOGICAL SCIENCES
(2023)
Article
Clinical Neurology
Marta Turri, Elisa Conti, Chiara Pavanello, Francesco Gastoldi, Marcella Palumbo, Franco Bernini, Vittoria Aprea, Francesca Re, Alberto Barbiroli, Davide Emide, Daniela Galimberti, Lucio Tremolizzo, Francesca Zimetti, Laura Calabresi, AGAINST AD Grp
Summary: The purpose of this study was to evaluate cholesterol esterification and HDL subclasses in plasma and cerebrospinal fluid (CSF) of Alzheimer's disease (AD) patients. The results showed that cholesterol esterification efficiency was reduced in the plasma of AD patients, and the unesterified cholesterol ratio was increased in CSF.
ALZHEIMERS RESEARCH & THERAPY
(2023)
Article
Clinical Neurology
Anthipa Chokesuwattanaskul, Harmony Jiang, Rebecca L. Bond, Daniel A. Jimenez, Lucy L. Russell, Harri Sivasathiaseelan, Jeremy C. S. Johnson, Elia Benhamou, Jennifer L. Agustus, Janneke E. P. van Leeuwen, Peerapat Chokesuwattanaskul, Chris J. D. Hardy, Charles R. Marshall, Jonathan D. Rohrer, Jason D. Warren
Summary: Abnormal reward processing is a characteristic of neurodegenerative diseases such as frontotemporal dementia and Alzheimer's disease, but the phenotypic repertoire and neuroanatomical substrates of abnormal reward behavior in these diseases are not fully understood. This study investigated these issues in a large patient cohort and identified four core, trans-diagnostic, and multimodal hedonic phenotypes.
BRAIN COMMUNICATIONS
(2023)
Article
Clinical Neurology
Ralph Buchert, Florian Wegner, Hans-Juergen Huppertz, Georg Berding, Matthias Brendel, Ivayla Apostolova, Carsten Buhmann, Alexander Dierks, Sabrina Katzdobler, Martin Klietz, Johannes Levin, Nima Mahmoudi, Andreas Rinscheid, Sophia Rogozinski, Jost-Julian Rumpf, Christine Schneider, Sophia Stoecklein, Phoebe G. Spetsieris, David Eidelberg, Mike P. Wattjes, Osama Sabri, Henryk Barthel, Guenter Hoeglinger
Summary: This study evaluated FDG-PET in a sample of 41 PSP patients and found that automatic covariance pattern analysis outperformed visual interpretation in detecting PSP-RS and provided useful sensitivity for vPSP. Pattern expression analysis is clinically useful in suspected PSP to complement visual reading and voxel-based testing.
MOVEMENT DISORDERS
(2023)
Article
Biology
Federico Zilio, Javier Gomez-Pilar, Ujwal Chaudhary, Stuart Fogel, Tatiana Fomina, Matthis Synofzik, Ludger Schols, Shumei Cao, Jun Zhang, Zirui Huang, Niels Birbaumer, Georg Northoff
Summary: EEG-based measures such as power-law exponent (PLE) and Lempel-Ziv complexity (LZC) can be used to identify biomarkers associated with complete locked-in syndrome (CLIS), allowing for better treatment and communication options.
COMMUNICATIONS BIOLOGY
(2023)
Article
Clinical Neurology
Grazia Devigili, Giulia Straccia, Emanuele Cereda, Barbara Garavaglia, Alessandro Fedeli, Antonio Emanuele Elia, Sylvie Helene Marie, Sylvie Helene Marie Jeanne Piacentini, Sara Prioni, Paolo Amami, Federica Invernizzi, Nico Golfre Andreasi, Luigi Michele Romito, Roberto Eleopra, Roberto Cilia
Summary: This study provides instrumental measures of autonomic dysfunction in GBA-PD patients and explores their correlation with non-motor symptoms. It shows that GBA-PD patients have more severe cardiovascular and sudomotor autonomic abnormalities compared to noncarriers, despite minimal clinical correlates. These findings highlight the importance of implementing instrumental autonomic assessment in GBA-PD patients.
MOVEMENT DISORDERS CLINICAL PRACTICE
(2023)
Article
Clinical Neurology
William Coath, Marc Modat, M. Jorge J. Cardoso, Pawel J. A. Markiewicz, Christopher A. D. Lane, Thomas D. Parker, Ashvini M. Keshavan, Sarah M. E. Buchanan, Sarah E. J. Keuss, Matthew J. Harris, Ninon Burgos, John Dickson, Anna L. Barnes, David L. Thomas, Daniel B. Beasley, Ian B. Malone, Andrew Wong, Kjell A. Erlandsson, Benjamin A. Thomas, Michael Scholl, Sebastien Ourselin, Marcus C. Richards, Nick C. M. Fox, Jonathan M. M. Schott, David M. Cash
Summary: The Centiloid scale aims to harmonize Aβ PET measures across different analysis methods. This study investigated the Centiloid transformation with PET/MRI data, finding that the transformation is valid but further understanding of the effects of acquisition or biological factors on using white matter as a reference is needed.
ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING
(2023)
Article
Clinical Neurology
Alberto Benussi, Valentina Cantoni, Mario Grassi, Ilenia Libri, Maria Sofia Cotelli, Barbara Tarantino, Abhishek Datta, Chris Thomas, Nadine Huber, Sari Karkkainen, Sanna-Kaisa Herukka, Annakaisa Haapasalo, Massimiliano Filosto, Alessandro Padovani, Barbara Borroni
Summary: This study investigated the use of cortico-spinal transcranial direct current stimulation (tDCS) in ALS patients through a randomized, double-blind, sham-controlled trial followed by an open-label phase. The results showed that tDCS significantly improved global strength, caregiver burden, and quality of life scores in ALS patients, and these improvements were correlated with the restoration of intracortical connectivity measures. Additionally, the number of completed tDCS treatments influenced patient survival.
Meeting Abstract
Clinical Neurology
C. Palleis, N. Franzmeier, E. Weidinger, S. Katzdobler, N. Albert, O. Sabri, H. Barthel, R. Rupprecht, B. S. Rauchmann, R. Perneczky, C. Haass, J. Levin, M. Brendel, G. U. Hoeglinger
MOVEMENT DISORDERS
(2023)
Meeting Abstract
Biochemistry & Molecular Biology
Emma Ehn, Jesper Eisfeldt, Hakan Thonberg, Jose Laffita, Jacqueline Schoumans, Anne Remes, Matti Viitanen, Anna Lindstrand, Inger Nennesemo, Caroline Graff
EUROPEAN JOURNAL OF HUMAN GENETICS
(2023)
Meeting Abstract
Clinical Neurology
E. Spinelli, A. Ghirelli, I. Bottale, S. Basaia, C. Cividini, M. Volonte, S. Galantucci, G. Magnani, F. Caso, E. Canu, V. Castelnovo, P. Caroppo, S. Prioni, C. Villa, K. Josephs, J. Whitwell, M. Filippi, F. Agosta
EUROPEAN JOURNAL OF NEUROLOGY
(2023)